IDDI Announces Collaborative Agreement with I-Biostat

Adverse Events

IDDI, announces that it has signed a collaborative agreement with I-BioStat, the Interuniversity Institute for Biostatistics and statistical Bioinformatics, which links research and consultancy groups at the Universities of Hasselt and Leuven in Belgium. The agreement will enable IDDI and I-Biostat to offer the full range of biostatistical services to the pharmaceutical and biotechnology sectors. Says Damien Tremolet, IDDI’s CEO: “This collaboration is a strategic move to position IDDI as the leading contract research organization offering biostatistical services for new drug development. This agreement is truly synergistic as it combines IDDI’s experience in data management, information technology and data analysis with I-BioStat’s track record in
cutting-edge statistical research.” Professor Geert Molenberghs, Director of IBiostat and a world opinion leader in biostatistics, adds: “The collaboration with IDDI will enable I-BioStat to deliver high-level consultancy to pharmaceutical and biotechnology companies, using the talent available at two Universities and a private company. It is aimed at combining academic excellence with a thorough understanding of the regulatory constraints of the health care sector.”


Fill this form to access to our file

    By submitting this form, you agree to receiving commercial electronic messages such as e-mails from IDDI. For more info, please visit our Privacy Policy. You can unsubscribe at any time by clicking the 'unsubscribe' button at the foot of any e-mail communication from IDDI.

    I authorize IDDI to use my data to contact me for commercial purposes.More information